Investing IdeasBrowse All StocksMarkets

Have your own idea? Try our Stock Screener

Header cover image

U.S. Pharma Industry Analysis

UpdatedNov 21, 2024
DataAggregated Company Financials
Companies298
  • 7D-3.8%
  • 3M-12.0%
  • 1Y9.8%
  • YTD4.5%

Over the last 7 days, the Pharma industry has dropped 5.3%, driven by Eli Lilly declining 7.2%. In the past year, the industry has gained 8.7%. Earnings are forecast to grow by 24% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 21 Nov 2024US$1.8tUS$373.8bUS$30.6b20.1x58.1x4.7x
Sat, 19 Oct 2024US$2.0tUS$365.3bUS$23.7b18.6x85.8x5.6x
Mon, 16 Sep 2024US$2.0tUS$364.3bUS$25.4b18.8x80.2x5.6x
Wed, 14 Aug 2024US$2.0tUS$362.1bUS$22.0b17.4x89x5.4x
Fri, 12 Jul 2024US$2.0tUS$357.6bUS$13.8b15.9x144.8x5.6x
Sun, 09 Jun 2024US$1.9tUS$358.3bUS$14.1b15.6x136.8x5.4x
Tue, 07 May 2024US$1.8tUS$358.0bUS$13.8b21.1x133.7x5.1x
Thu, 04 Apr 2024US$1.9tUS$355.2bUS$22.7b24.6x82.9x5.3x
Sat, 02 Mar 2024US$1.9tUS$355.3bUS$22.5b24.1x83.8x5.3x
Mon, 29 Jan 2024US$1.8tUS$375.2bUS$33.9b24.6x52.1x4.7x
Wed, 27 Dec 2023US$1.7tUS$375.2bUS$33.9b31.8x49.3x4.4x
Fri, 24 Nov 2023US$1.6tUS$375.1bUS$33.9b25.9x48.2x4.4x
Sun, 22 Oct 2023US$1.7tUS$382.7bUS$44.7b17.6x37x4.3x
Tue, 19 Sep 2023US$1.7tUS$381.8bUS$43.9b18.5x39.1x4.5x
Thu, 17 Aug 2023US$1.8tUS$381.7bUS$44.0b19.1x40.2x4.6x
Sat, 15 Jul 2023US$1.7tUS$392.8bUS$60.2b18.3x27.7x4.2x
Mon, 12 Jun 2023US$1.7tUS$393.0bUS$60.5b18.6x28.4x4.4x
Wed, 10 May 2023US$1.7tUS$395.1bUS$56.8b19.4x30.7x4.4x
Fri, 07 Apr 2023US$1.7tUS$401.2bUS$69.4b15.9x23.8x4.1x
Sun, 05 Mar 2023US$1.6tUS$401.2bUS$69.4b16.9x22.5x3.9x
Tue, 31 Jan 2023US$1.6tUS$402.6bUS$69.4b17.8x23.7x4.1x
Thu, 29 Dec 2022US$1.7tUS$403.7bUS$70.7b16.6x24.6x4.3x
Sat, 26 Nov 2022US$1.7tUS$403.7bUS$70.7b16.9x24.7x4.3x
Mon, 24 Oct 2022US$1.6tUS$403.4bUS$72.1b13.2x22.5x4x
Wed, 21 Sep 2022US$1.6tUS$403.0bUS$71.3b13.1x21.8x3.9x
Fri, 19 Aug 2022US$1.6tUS$402.8bUS$70.2b15.8x23.4x4.1x
Sun, 17 Jul 2022US$1.7tUS$392.4bUS$65.1b22x26.1x4.3x
Tue, 14 Jun 2022US$1.6tUS$392.5bUS$64.7b19.9x24.3x4x
Thu, 12 May 2022US$1.6tUS$392.3bUS$64.5b19.1x24.9x4.1x
Sat, 09 Apr 2022US$1.7tUS$373.8bUS$60.7b22.4x28.5x4.6x
Mon, 07 Mar 2022US$1.6tUS$373.6bUS$60.3b19.7x25.9x4.2x
Wed, 02 Feb 2022US$1.6tUS$363.7bUS$40.7b21.3x39.2x4.4x
Fri, 31 Dec 2021US$1.7tUS$361.1bUS$37.9b23x44.1x4.6x
Sun, 28 Nov 2021US$1.6tUS$361.1bUS$38.1b23.4x41.4x4.4x
Price to Earnings Ratio

41.4x


Total Market Cap: US$1.6tTotal Earnings: US$38.1bTotal Revenue: US$361.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 49.3x202220232024
Current Industry PE
  • Investors are optimistic on the American Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 58.0x which is higher than its 3-year average PE of 49.3x.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 7.1% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.04%
Healthcare-3.31%
Pharma-3.80%
Pharma-3.80%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RPRX Royalty PharmaUS$26.221.4%
+US$164.4m		-3.5%PE10.2x
VRNA Verona PharmaUS$38.855.2%
+US$157.1m		176.5%PS565.3x
VTRS ViatrisUS$13.131.0%
+US$155.2m		40.1%PS1x
ACRS Aclaris TherapeuticsUS$3.9662.3%
+US$108.6m		386.3%PS10.4x
OMER OmerosUS$6.0343.9%
+US$106.6m		235.0%PE-1.9x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

JAZZ

US$119.24

Jazz Pharmaceuticals

7D

-6.6%

1Y

-2.0%

LLY

US$753.41

Eli Lilly

7D

-7.2%

1Y

26.6%

PFE

US$24.94

Pfizer

7D

-6.7%

1Y

-17.7%

BMY

US$57.88

Bristol-Myers Squibb

7D

-0.9%

1Y

17.1%

MRK

US$97.44

Merck

7D

-1.1%

1Y

-4.2%

ACRS

US$3.96

Aclaris Therapeutics

7D

62.3%

1Y

386.3%

PRGO

US$27.15

Perrigo

7D

1.3%

1Y

-10.8%

Perrigo Company: Great Combination Of Future Growth With A Low Valuation

Nov 19

ZTS

US$175.67

Zoetis

7D

-0.8%

1Y

-2.1%

Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy

Nov 18

TEVA

US$17.03

Teva Pharmaceutical Industries

7D

0.5%

1Y

80.0%

Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Nov 17
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

OMER

US$6.03

Omeros

7D

43.9%

1Y

235.0%

Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns

Nov 17

HROW

US$42.44

Harrow

7D

-18.1%

1Y

361.8%

Harrow: Spotlight On IHEEZO

Nov 16

ELAN

US$13.44

Elanco Animal Health

7D

-5.3%

1Y

12.7%

Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals

Nov 15
Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals

RPRX

US$26.22

Royalty Pharma

7D

1.4%

1Y

-3.5%

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Nov 13
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

VTRS

US$13.13

Viatris

7D

1.0%

1Y

40.1%

VRNA

US$38.85

Verona Pharma

7D

5.2%

1Y

176.5%

GHRS

US$10.95

GH Research

7D

18.5%

1Y

58.5%

We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

Oct 11
We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely